Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Dru...(sistant to other quinolones. The Company...),Health

Date:4/2/2009

sistant to other quinolones. The Company recently announced positive results from a Phase 2 trial utilizing the IV formulation of delafloxacin in complicated skin and skin structure infections (cSSSI). Delafloxacin successfully completed two previous Phase 2 trials with the oral formulation. In large panel microbiological testing, the compound has been shown to be at least 32-fold more potent than levofloxacin, ciprofloxacin, gatifloxacin and moxifloxacin against quinolone-resistant MRSA (MIC90 of less than or equal to 0.5 ug/ml for delafloxacin versus > 16 ug/ml for all other quinolones) and twice as potent as daptomycin against MRSA. Delafloxacin has also been shown to be more potent than existing quinolones against a range of Gram-positive, anaerobic and Gram-negative organisms. Rib-X is currently developing both IV and oral formulations of delafloxacin for use in surgical prophylaxis and other therapeutic arenas within the over $9.9 billion hospital antibiotic market.(2)

About cSSSI

Complicated skin and skin structure infections (cSSSI) encompass a wide range of serious infections involving the deeper soft tissue, including severe cellulitis and major abscesses. These infections may occur in patients with skin ulcers or burns, as well as patients who have undergone surgery or experienced other kinds of trauma. These infections affect over one million patients in the U.S. annually and are most commonly caused by Gram-positive bacteria, specifically Staphylococcus aureus and methicillin-resistant S. aureus (MRSA).

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an ess
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
2. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
3. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
4. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
5. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
6. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
7. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
8. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
9. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
10. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
11. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.